AlphaStocks
5.6
Consider Buy

Neogenomics Inc (NEO)

As of Sep 20, 2026, Neogenomics Inc (NEO) scores 5.6/10 on AlphaStocks' five-model composite, #72 of 168 Health Care stocks.

Health Care / Health Care Services

S&P SmallCap 600

$19.90

Middle of the pack. No strong signal either way.

Consider Buy

Score based on 4 of 5 models — moderate confidence

Data as of Sep 20, 2026

#72out of 168 in Health Care

Is NEOGENOMICS INC a Good Investment in 2026?

NEOGENOMICS INC (NEO) scores 5.6 out of 10 on AlphaStocks' composite model, earning a Consider Buy rating. The Piotroski model rates NEOGENOMICS INC as Attractive (5/9). However, the Greenblatt Magic Formula model rates it Caution — Earnings yield -5.8% · ROC -31%. NEOGENOMICS INC ranks #72 out of 168 stocks in the Health Care sector.

This summary is algorithmically generated and is not financial advice.

Key Metrics

ROE-8.5Market Cap3B

Valuation

Currently unprofitable — fair value estimate not available.

Fair value estimate not available for this stock.

5-Model Analysis

Each model evaluates this stock from a different angle. Combined, they form the composite score above.

Piotroski

Attractive

5/9

Buffett

Caution

Business quality & competitive moat

Graham

Neutral

Price vs intrinsic value

Lynch

Neutral

Growth rate vs price (PEG)

Greenblatt

Caution

Earnings yield -5.8% · ROC -31%

Frequently Asked Questions

Is NEOGENOMICS INC (NEO) a good investment?
As of Sep 20, 2026, Neogenomics Inc (NEO) scores 5.6/10 on AlphaStocks' five-model composite, #72 of 168 Health Care stocks. That is a middle-of-the-pack score with no strong signal either way. Currently unprofitable — fair value estimate not available.
What is NEOGENOMICS INC's Piotroski F-Score?
NEOGENOMICS INC's Piotroski F-Score status is Attractive. The raw score is 5/9. The Piotroski F-Score evaluates financial health using 9 fundamental signals including profitability, leverage, and operating efficiency.
Is NEO overvalued or undervalued?
A precise fair value estimate is not available for NEO. Currently unprofitable — fair value estimate not available.
How does NEO compare to other Health Care stocks?
NEOGENOMICS INC ranks #72 out of 168 stocks in the Health Care sector, placing it in the top 43% of its sector by composite score. This is an above-average position relative to sector peers.
What do investment models say about NEO?
AlphaStocks evaluates NEO using five proven investment models. Piotroski: Attractive; Buffett: Caution; Graham: Neutral; Lynch: Neutral; Greenblatt Magic Formula: Caution. These models are combined into a single composite score of 5.6/10.

Similar Stocks

DVAMDDGX

Compare NEO with

DVA vs NEOMD vs NEODGX vs NEOAZN vs NEOBFAM vs NEO

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer